On June 3, 2022 Patrys reported that share news that the Telethon Kids Institute has been awarded significant funding from the Cure Brain Cancer Foundation to support research for Patrys’ PAT-DX1 and PAT-DX3 programs (Press release, Patrys, JUN 3, 2022, View Source [SID1234615602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The grant will be used to investigate Patrys’ deoxymab assets PAT-DX1 and PAT-DX3 in both in vitro and in vivo studies of high grade glioma (HGG), by combining with standard of care (SOC) treatments such as radiotherapy and temozolomide to determine efficacy.

Based within the Perth Children’s Hospital, the Telethon Kids Institute conducts translational research focused on improving treatments for the health and wellbeing of children. The research will be led by Professor Terrance Johns, who is at the forefront of Australian brain cancer research.

Patrys CEO and Managing Director, Dr James Campbell, said:

"This is one of our most exciting collaborations to date. Professor Terrance Johns and his team are pivotal in the brain cancer space in Australia. We gratefully acknowledge the Cure Brain Cancer Foundation Clinical Accelerator grant scheme for providing funding for therapeutic products with the potential to improve the pathway to the clinic."